Cortex Welcomes AAIPharma Services/ Cambridge Major Laboratories to Innovation Community

The Cortex Innovation Community ( today announced the addition of AAIPharma Services Corp. / Cambridge Major Laboratories, Inc. (AAI/CML), a world-class supplier of comprehensive pharmaceutical development, analytical and manufacturing services, as the latest member of the 200-acre innovation district in St. Louis City.

AAI/CML will invest $10.7 million in area operations and add more than 100 highly skilled workers — including some 30 new positions — to the Cortex district. By Fall 2016, the company will move from its south St. Louis County location on S. Lindberg Blvd., into the newest Cortex building — the soon-to-be-complete 4260 Building located at 4260 Forest Park Parkway — occupying 37,500-square-feet.

“We are thrilled to welcome AAIPharma / Cambridge Major Labs to our dynamic innovation community,” said Dennis Lower, president of the Cortex Innovation Community. “While our recent growth has come from software technology companies like Uber, Pandora and Square joining Cortex, adding a progressive leader in the bioscience space builds on another one of our core strengths.”

In 2013, AAIPharma Services Corp., joined with Cambridge Major Laboratories, Inc., to form a fully integrated custom development and manufacturing organization. The company is now a leading provider of custom manufacturing and development services for the pharmaceutical and biotechnology industries, with nearly 1,000 worldwide employees operate out of seven sites in the U.S. and Europe. It’s St. Louis analytical testing facility employs approximately 80 full time staff and specializes in analytical testing for the drug manufacturing and packaging industries including raw material testing, drug product release and stability, and environmental monitoring for both sterile and non-sterile drugs. AAI/CML provides program management and innovative solutions for drug developers and manufacturers in the areas of small molecules, microbiologics, chemicals and biopharmaceuticals.

“This expansion comes at a critical time in our company’s growth. We expect to invest $10.7M in capital over the next twelve to eighteen months to build and outfit our new analytical testing facility and we are very excited to be working with Cortex and the Governor’s office to provide jobs for the greater St. Louis area,” said Stephan Kutzer, CEO, President and Chairman of AAI/CML.

Founded in 2002 through a collaboration between Washington University in St. Louis, BJC Healthcare, the University of Missouri-St. Louis, Saint Louis University, and the Missouri Botanical Garden, Cortex has grown into the Midwest’s premier innovation hub of bioscience and technology research, development and commercialization, and was recently cited by the Brookings Institution as a model of urban innovation districts.

Cortex is home to more than 200 software, consumer product and bioscience technology firms, ranging from mature enterprises such as DuPont, Boeing, AB Mauri, Square, Stereotaxis, the Cambridge Innovation Center (CIC) and Washington University among others, to promising early-stage startups like Aisle411, CoFactor Genomics, and Pushup Social.

“Innovation is quickly becoming the calling card of today’s businesses based in St. Louis City,” said St. Louis City 17th Ward Alderman Joe Roddy, whose district includes Cortex. “Cortex has become a national example of where our economy is going and we’re thrilled to welcome AAI/CML into the fold.”